Bicara Therapeutics (BCAX) Net Income towards Common Stockholders (2023 - 2026)

Bicara Therapeutics' Net Income towards Common Stockholders history runs 4 years deep, the most recent figure standing at -$56.2 million for Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders fell 52.56% year-over-year to -$56.2 million in Q1 2026; TTM through Mar 2026 was -$157.3 million, a 70.38% decrease from a year earlier, with the FY2025 full-year figure at -$138.0 million, down 102.88% from the prior year.
• Net Income towards Common Stockholders slipped to -$56.2 million in Q1 2026 per BCAX's latest filing, from -$37.4 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at -$12.4 million in Q4 2023 and bottomed at -$56.2 million in Q1 2026.
• The 4-year median for Net Income towards Common Stockholders is -$22.8 million (2023), against an average of -$27.0 million.
• Across the five-year window, Net Income towards Common Stockholders gained 23.48% in 2024 and sank 194.58% in 2025, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$12.4 million in 2023, then plunged by 68.46% to -$21.0 million in 2024, then tumbled by 78.39% to -$37.4 million in 2025, then sank by 50.35% to -$56.2 million in 2026.
• Per Business Quant, the three latest BCAX Net Income towards Common Stockholders figures stand at -$56.2 million (Q1 2026), -$37.4 million (Q4 2025), and -$36.3 million (Q3 2025).